Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates
The present disclosure provides antibody-drug conjugate structures, where the antibody-drug conjugate includes a cleavable linker containing an ester group that links the antibody to the drug. The disclosure also encompasses compounds and methods for production of such conjugates. In addition, the disclosure also encompasses pharmaceutical compositions and methods of using the conjugates.
1 . A conjugate of formula (I):
wherein:
W 1 is a drug;
W 2 is a polypeptide;
A is an amino acid residue, where k is 0 or an integer from 1 to 5;
L is a linker;
G is a conjugation moiety;
X 1 is selected from:
and —(CHR 1 ) j (CHR 2 )—;
R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl and R 3 , wherein R 1 optionally substituted with R 3 ;
j is 0 or an integer from 1 to 5;
R 2 is R 3 ; or R 2 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, wherein R 2 is substituted with R 3 ;
X 2 is —NH— or —C(O)—;
each R 3 is independently a glycoside or glycoside derivative.
2 . The conjugate of claim 1 , wherein X 1 is
3 . The conjugate of claim 1 , wherein X 1 is —(CHR 1 ) j (CHR 2 )—.
4 . The conjugate of claim 3 , wherein j is 0.
5 . The conjugate of claim 4 , wherein R 2 is alkyl.
6 . The conjugate of claim 4 , wherein R 2 is aryl.
7 . The conjugate of claim 3 , wherein j is 1.
8 . The conjugate of claim 7 , wherein R 1 is hydrogen.
9 . The conjugate of claim 7 , wherein R 1 is substituted with R 3 .
10 . The conjugate of claim 1 , wherein each R 3 is independently selected from:
11 . The conjugate of claim 1 , wherein the conjugate is of formula (II):
wherein R 4 is an amino acid side chain.
12 . The conjugate of claim 11 , wherein the conjugate is selected from:
13 . The conjugate of claim 1 , wherein the conjugate is of formula (III):
wherein R 4 is an amino acid side chain.
14 . The conjugate of claim 13 , wherein the conjugate is selected from:
15 . The conjugate of claim 1 , wherein k is 2.
16 . The conjugate of claim 1 , wherein L comprises:
-(T 1 -V 1 ) a -(T 2 -V 2 ) b -(T 3 -V 3 ) c -(T 4 -V 4 ) d -(T 5 -V 5 ) e -(T 6 -V 6 ) f -,
wherein
a, b, c, d, e and f are each independently 0 or 1;
T 1 , T 2 , T 3 , T 4 , T 5 and T 6 are each independently selected from a covalent bond, (C 1 -C 12 )alkyl, substituted (C 1 -C 12 )alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w , (PEG) n , (AA) p , —(CR 13 OH) m —, 4-amino-piperidine (4AP), meta-amino-benzyloxy (MABO), meta-amino-benzyloxycarbonyl (MABC), para-amino-benzyloxy (PABO), para-amino-benzyloxycarbonyl (PABC), para-aminobenzyl (PAB), para-amino-benzylamino (PABA), an acetal, a hydrazine, a disulfide, and an ester, wherein EDA is an ethylene diamine moiety, PEG is a polyethylene glycol, and AA is an amino acid residue or an amino acid analog, wherein each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12;
V 1 , V 2 , V 3 , V 4 , V 5 and V 6 are each independently selected from the group consisting of a covalent bond, —CO—, —NR 15 —, —NR 15 (CH 2 ) q —, —NR 15 (C 6 H 4 )—, —CONR 15 —, —NR 15 CO—, —C(O)O—, —OC(O)—, —O—, —S—, —S(O)—, —SO 2 —, —SO 2 NR 15 —, —NR 15 SO 2 — and —P(O)OH—, wherein each q is an integer from 1 to 6;
each R 13 is independently selected from hydrogen, an alkyl, a substituted alkyl, an aryl, and a substituted aryl; and
each R 15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.
17 . The conjugate of claim 16 ,
wherein:
T 1 is (C 1 -C 12 )alkyl and V 1 is —CO—;
T 2 is an amino acid analog and V 2 is —NH—;
T 3 is (PEG) n and V 3 is —CO—; and
d to f are each 0; or
wherein:
T 1 is (C 1 -C 12 )alkyl and V 1 is —CO—;
T 2 is an amino acid analog and V 2 is —NH—;
T 3 is (PEG) n and V 3 is —CONH—;
T 4 is (PEG) n and V 4 is —CO—;
e and f are each 0.
18 . The conjugate of claim 1 , wherein G is:
wherein:
Z is CR 10 or N,
R 7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
R 8 and R 9 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, or R 8 and R 9 are optionally cyclically linked to form a 5 or 6-membered heterocyclyl;
each R 10 is independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acyl amino, amino acyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.
19 . The conjugate of claim 1 , wherein G is selected from an acetal, a hydrazone, an oxime, a sulfide, a disulfide, a triazole, an ester, and an amide.
20 . A compound of formula (IV):
wherein:
W 1 is a drug;
A is an amino acid residue, where k is 0 or an integer from 1 to 5;
L is a linker;
G is a conjugation moiety;
X 1 is selected from:
and —(CHR 1 ) j (CHR 2 )—;
R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl and R 3 , wherein R 1 is optionally substituted with R 3 ;
j is 0 or an integer from 1 to 5;
R 2 is R 3 ; or R 2 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, wherein R 2 is substituted with R 3 ;
X 2 is —NH— or —C(O)—;
each R 3 is independently a glycoside or glycoside derivative.
21 .- 38 . (canceled)
39 . A pharmaceutical composition comprising:
a conjugate of claim 1 ; and
a pharmaceutically-acceptable excipient.
40 . A method comprising:
administering to a subject a conjugate of claim 1 .